UnitedHealth Group Incorporated (UNH) Stock Analysis
Healthcare · Healthcare Plans
Sell if holding. Analyst target reached at $407.21 — A.R:R is negative (-1.2) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: risk-based products (80.0%).
UnitedHealth Group operates Optum (health services and pharmacy, serving 95 million consumers through Optum Health) and UnitedHealthcare (health benefits for employers, individuals, Medicare, and Medicaid). Revenue is predominantly generated through risk-based health insurance... Read more
Sell if holding. Analyst target reached at $407.21 — A.R:R is negative (-1.2) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: risk-based products (80.0%). Chart setup: No clear chart pattern; technical signals are mixed. Score 4.8/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 30d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and news legal. Suitability: moderate.
About UnitedHealth Group Incorporated
About UnitedHealth Group Incorporated
UnitedHealth Group's health benefit plans covered 29.7 million Employer & Individual members, 8.4 million Medicare Advantage enrollees, and nearly 7.4 million Medicaid members across 32 states and the District of Columbia as of December 31, 2025. CMS premium revenues represented 44% of total consolidated revenues in 2025, and risk-based premiums constituted nearly 80% of all revenues. Optum Rx managed $188 billion in pharmaceutical spending, including nearly $87 billion in specialty pharmaceuticals, through a network of approximately 64,000 retail pharmacies.
UnitedHealth Group earns revenue through two complementary mechanisms. UnitedHealthcare charges monthly premiums to cover medical and administrative costs across employer, individual, Medicare, and Medicaid markets: Medicare Advantage premiums are set by CMS based on geographic area, demographic factors, and health status, while Medicaid premiums are negotiated under state contracts. UnitedHealthcare Community & State operated in 32 states and the District of Columbia as of December 31, 2025, serving nearly 7.4 million people through CHIP, Dual SNPs, Long-Term Services and Supports, and Medicaid expansion in 19 states. Optum's three businesses — Optum Health (patient-centered care for 95 million consumers), Optum Insight (analytics and technology services with a $31.1 billion backlog as of December 31, 2025), and Optum Rx (pharmacy benefit management) — generate fee, performance, and spread-based revenue. Optum Insight's $31.1 billion backlog included $18.3 billion expected to be recognized within 12 months and $12.9 billion related to affiliated agreements.
Show full overview
CMS's 44% share of consolidated revenues exposes UnitedHealth Group to annual Medicare Advantage rate-setting decisions. CMS retains the right to audit medical loss ratios and risk adjustment data submissions, with premium payments varying based on geographic area, demographics, and enrollee health status — all set externally each year. The 10-K notes that relatively small differences between predicted and actual medical costs as a percentage of revenues have resulted and may in future periods result in significant financial impact, a sensitivity amplified by the nearly 80% share of revenues tied to risk-based arrangements where cost overruns cannot be recovered within the fixed premium year.
See also: Healthcare · Healthcare Plans
From UnitedHealth Group Incorporated's most recent 10-K filing, extracted June 16, 2026.
Recent developments
updated 2026-06-17Recent Developments — UnitedHealth Group Incorporated
Latest news
- NEWS Mark Cuban Pushes 'Service Level Agreements' For Healthcare, Warns Failed Policies Should End — benzinga Jun 15, 2026 neutral
- NEWS Patients Denied Care, Then Approved Later? Federal Watchdog Raises Medicare Advantage Concerns — benzinga Jun 11, 2026 negative
- NEWS 7 Health Care Stocks With Whale Alerts In Today's Session — benzinga Jun 9, 2026 neutral
- NEWS Mizuho Maintains Outperform on UnitedHealth Group, Raises Price Target to $460 — benzinga Jun 8, 2026 positive
- NEWS AbbVie, UnitedHealth, Sabra Health Care And A Consumer Defensive Stock On CNBC's 'Final Trades' — benzinga Jun 8, 2026 neutral
Generated 2026-06-17T09:07:23Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMCustomerCMS44%10-K Item 1: 'Premium revenues from CMS represented 44% of UnitedHealth Group's total consolidated revenues for the year ended December 31, 2025'
- HIGHProductrisk-based products80%10-K Item 1A: 'Premium revenues from risk-based products constitute nearly 80% of our total consolidated revenues'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $407.21 — A.R:R is negative (-1.2) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: risk-based products (80.0%). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $388.23. Score 4.8/10, moderate confidence.
Take-profit target: $405.87 (-0.4% upside). Prior stop was $388.23. Stop-loss: $388.23.
Concentration risk — Product: risk-based products (80.0%); Analyst target reached - limited upside remaining; Near 52-week high (2.0% away).
UnitedHealth Group Incorporated trades at a P/E of 31.0 (forward 19.7). TrendMatrix value score: 4.8/10. Verdict: Sell.
34 analysts cover UNH with a consensus score of 3.9/5. Average price target: $407.
What does UnitedHealth Group Incorporated do?UnitedHealth Group operates Optum (health services and pharmacy, serving 95 million consumers through Optum Health) and...
UnitedHealth Group operates Optum (health services and pharmacy, serving 95 million consumers through Optum Health) and UnitedHealthcare (health benefits for employers, individuals, Medicare, and Medicaid). Revenue is predominantly generated through risk-based health insurance premiums (nearly 80% of total revenues), with CMS premiums representing 44% of consolidated revenues in 2025 from Medicare Advantage's 8.4 million enrollees and Medicaid programs across 32 states.